Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of First Cycle Optimization for Regorafenib Treatment Compared to Standard Dose of Regorafenib in Patients With HCC Who Failed Any 1st Line Systemic Treatment and for Whom the Physician is Intending to Treat With Regorafenib

NCT04476329 is registered in ClinicalTrials.gov with SC Liver Research Consortium, LLC as lead sponsor.

NCT NCT04476329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04476329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of First Cycle Optimization for Regorafenib Treatment Compared to Standard Dose of Regorafenib in Patients With HCC Who Failed Any 1st Line Systemic Treatment and for Whom the Physician is Intending to Treat With Regorafenib
Lead sponsor
SC Liver Research Consortium, LLC
Phase
Phase 2
Overall status
Terminated
Start date
January 21, 2021
Completion date
December 10, 2021
Enrollment
7 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma